Zydus Lifesciences Ltd (ZYDUSLIFE) Q1 FY27 Earnings Call: Revenue Surges 22% YoY, Maintains 24%+ EBITDA Margin Guidance

Zydus Lifesciences Ltd held its Q1 FY27 earnings call on August 11, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Double-Digit Start to FY 2026-2027

• Consolidated revenue of Rs.80.2 Bn in Q1 FY2026-2027, up 22% YoY, driven by broad-based momentum across India formulations, international markets, and consumer wellness.
• EBITDA margin of 24.1% (Rs.19.3 Bn EBITDA), in line with the maintained FY 2026-2027 guidance of 24%+, despite higher investment costs in Saro and R&D.
• Net profit of Rs.9.4 Bn in Q1 FY2026-2027; net debt/EBITDA at a comfortable 0.7x, reflecting a strong balance sheet post the Assertio acquisition.
• India branded formulations grew 20% YoY, outperforming the market consistently over the last 3 fiscals; chronic/sub-chronic portfolio share reached 54.2% (AWACS MAT Jun 2026, +360 bps over 4 years).
• Consumer wellness revenue of Rs.14.3 Bn, up 67% YoY, with domestic wellness like-to-like growth of 25%; skin/hair care +35%, food/nutrition +16%. Seasonal brands de-grew due to a softer summer.

India Leads, US Steady, Consumer Wellness Surges

• India formulations branded business delivered 20% growth in Q1 FY2026-2027, driven by chronic portfolio and innovation uptake; management expects India to grow mid-teens in FY 2026-2027, outperforming the market by 300–500 bps.
• North America (US + Canada) revenue of Rs.31 Bn in Q1, up 5% QoQ; US business expected to deliver single-digit growth in FY 2026-2027, with potential for double-digit growth in FY 2027-2028 driven by the generic and branded pipeline.
• International formulations revenue of Rs.9.7 Bn, up 34% YoY, crossing $100M in the quarter; growth led by core emerging markets, Europe (France, Spain, UK), and new market innovation/ first-to-market generics.
• Consumer wellness revenue of Rs.14.3 Bn (+67% YoY); management expects the entire consumer business to deliver double-digit growth in FY 2026-2027, with Comfort Click business also guiding to strong double-digit growth.
• Medical devices revenue of Rs.2.8 Bn in Q1 FY2026-2027; the Andy robot surgical system is being expanded.
• Domestic business growth of ~20% was driven by core products rather than semaglutide; management called the semaglutide trend sustainable but a small contributor.

Regulatory Milestones and Late-Stage Trials Across Therapies

• Saroglitazar Magnesium NDA for PBC granted priority review by the US FDA in Q1 FY2026-2027; rolling Phase 3 trial ongoing and pre-launch capabilities being built. A marginal ALP trial is about to start to expand the addressable market. Expanded indication not near-term; expected to take 2–3 years (potentially by FY 2028-2029 or later).
• Desidustat received regulatory approval in India to initiate a Phase 3 trial for sickle cell disease, in collaboration with ICMR, in Q1 FY2026-2027. Approved in China with API supply for formulation manufacturing; nationally reimbursed but needs NRDL approval for major market share. No meaningful scale from Desidustat factored for FY 2026-2027.
• Uznoplast for ALS: Phase 2 trial in the US enrolling 240 patients vs placebo; data readout expected by end of FY 2027-2028 (FY28) or late calendar 2028/early 2029. Uznoplast for ulcerative colitis: Phase 2a data positive; Phase 2b/3 being planned in India with potential US evaluation.
• 505(b)(2) portfolio reached 10% of business (19 in-house + 8 licensed products; 4+ commercialized); management expects it to cross 15% by end of FY 2026-2027 and become profitable. Liquid portfolio: 7 launches, 10+ approvals. Larger scale-up expected in FY 2027-2028.
• Biotech R&D: Phase 3 clinical trials in India initiated for the second ADC biosimilar in Q1 FY2026-2027. Vaccines R&D: Phase 2 of bivalent typhoid conjugate vaccine completed; Phase 1 of chikungunya vaccine initiated in India; MR vaccine dossier submitted to WHO and accepted for review.
• Appli-Bersat biosimilar launch in India showed good initial traction in Q1 FY2026-2027; management described it as critical with high-quality specifications required for ophthalmology and expects it to be a meaningful contributor. The company has not in-licensed the innovator brand (Ailia) for this molecule.

Margin Floor Maintained Despite Heavy Investment Phase

• EBITDA margin guidance for FY 2026-2027 maintained at 24%+ (Q1 at 24.1%); management reiterated that investments in biologics, vaccines, and MedTech are already baked into guidance, with no major incremental spend expected as these businesses scale.
• Other expenses (ex-R&D) quarterly run rate guided at Rs.1,900–2,000 Cr for FY 2026-2027, with ~80% of the QoQ increase attributed to acquisitions. Full-year capex guided at Rs.1,500–1,600 Cr, driven by SCZ 3 facility, capacity expansions, new R&D center, wellness land acquisition, and new biologics/vaccines facilities.
• Q1 FY2026-2027 gross margin dip (sequential and YoY) attributed to higher cost from the Mira background settlement with the innovator; Mira remains a strong profitability driver.
• Consolidated depreciation increased sharply from Q4 FY2025-2026 and Q1 FY2026-2027 due to acquisitions and licensing amortization (including Mirabegron); amortization will continue through Q1 FY2027-2028 and end by Q2 FY2027-2028 (specific amount undisclosed for confidentiality).
• Saro (TAD) launch targeted for April 2027 (FY 2027-2028); first two years post-launch seen as an investment phase with revenue build-up in years 2–3. Management conservatively estimates Saro peak sales at $200–300M (optimistic scenario crossing $400M, period unspecified).
• Management aspires to expand EBITDA margins to 28–30% as it moves closer to the 5-year target period around FY30, citing branded business mix improvement and scale-up of biologics/vaccines as key levers.

Branded Share Rising; Biosimilars and 505(b)(2) Drive Long-Term Outlook

• US branded business contributed ~10% of US revenue in Q1 FY2026-2027 (~$130–135M annualized); Rolvedon (from Assertio acquisition) expected to add $15–20M per quarter from Q2 FY2026-2027, pushing branded share to ~15%. Rare disease (ultra-rare) revenue was $60M in FY2025-2026; the remaining $60–70M came from the 505(b)(2) portfolio.
• Filed 5 ANDAs, received 9 approvals, launched 11 products in Q1 FY2026-2027; management plans 30–40 US launches for FY 2026-2027 (minimum 30), including specialty launches. Enalapril launch secured 180-day exclusivity.
• No expected dip in US revenues over the next 3–4 years, supported by a growing pipeline including 505(b)(2) products and the Enalapril exclusivity. The 505(b)(2) portfolio scale-up is expected larger in FY 2027-2028.
• US biosimilars portfolio: management "expects the first meaningful sales buildup in calendar year 2029", preceded by a couple of product launches. Injectable facility at Zydus Biotech Park received EIR with VAI classification after GMP inspection (Apr–May 2026).
• Management targets branded business to reach 2/3 of overall operations in the medium term, which is expected to improve margins. Innovation portfolio and value-based biosimilars showed exceptional growth in Q1 FY2026-2027.
• Joint venture with Sunshine Healthcare to build a pharma manufacturing facility in Sri Lanka, aimed at reducing import dependence. Purchase price allocation for the Assertio acquisition expected within 12 months, with a large portion allocated to intangible assets (brand and commercial platform). No amortization from the acquisition was recorded in Q1 FY2026-2027.